Needham initiated coverage of BioAge Labs (BIOA) with a Buy rating and $50 price target The firm is “bullish” on the company’s lead asset BGE-102, an oral, NLRP3 inhibitor in Phase 1 development for cardiovascular risk in obese patients. BGE-102’s safety and early biomarker data demonstrate “best-in-class potential in a very large indication,” the analyst tells investors in a research note. Needham sees a favorable risk/reward for the shares ahead of several catalysts in the next 12-15 months.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA:
- BioAge Labs: Early-Stage Promise in APJ Agonists Balanced by Execution Risk Supports Hold Rating
- BioAge Labs files automatic mixed securities shelf
- BioAge Highlights BGE-102 Progress and Financial Strength
- BIOA Earnings this Week: How Will it Perform?
- BioAge Labs price target raised to $52 from $15 at Citi